Direkt zum Inhalt
Merck

In vitro and in vivo evaluation of a melamine dendrimer as a vehicle for drug delivery.

International journal of pharmaceutics (2004-08-04)
Michael F Neerman, Wen Zhang, Alan R Parrish, Eric E Simanek
ZUSAMMENFASSUNG

Cell-based and acute and subchronic in vivo toxicity profiles of a dendrimer based on melamine reveal that this class of molecules warrants additional study as vehicles for drug delivery. In cell culture, a substantial decrease in viability was observed at 0.1 mg/mL. For the acute studies, mice were administered 2.5, 10, 40 and 160 mg/kg of dendrimer via i.p. injection. At 160 mg/kg, 100% mortality was seen 6-12 h after injection. For the other cohorts, blood chemistry work revealed no renal damage was taking place at 48 h. Liver enzyme activity nearly doubled for the mice treated at 40 mg/kg suggesting hepatotoxicity. For the subchronic studies, three i.p. injections of 2.5-40 mg/kg of dendrimers were administered at 3-week intervals. No mortality was observed. Forty-eight hours following the last administration, blood chemistry revealed no renal damage, but liver damage was indicated by elevated serum enzyme activity at the highest dose. Histopathological data further confirms that doses up to 10 mg/kg show no hepatic damage at subchronic doses. However, subchronic doses at 40 mg/kg lead to extensive liver necrosis.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Melamin, 99%
Supelco
Melamin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Melamin, analytical standard
USP
Melamin, United States Pharmacopeia (USP) Reference Standard